Newborn Screening for Glutaric Aciduria-II: The New... [JIMD Rep. 2013] - PubMed - NCBI
Newborn screening for Glutaric Aciduria-II: The New England experience
Sahai I, et al. JIMD Rep 2013 Nov
Newborn screening for severe T and B cell immunodeficiency in Israel: a pilot study
Somech R, et al. Isr Med Assoc J 2013 Aug;15(8):404-9
Reduction in newborn screening metabolic false-positive results following a new collection protocol.
Mindy Morris et al. Genetics in Medicine, Oct 31
Systematic data collection to inform policy decisions: integration of the Region 4 Stork (R4S) collaborative newborn screening database to improve MS/MS newborn screening in Washington State
Fleischman A, et al. JIMD Rep 2013 Nov
Inborn error testing: Immunodeficiency disease added to newborn screening program, Spectroscopy Now, Steve Down, Nov 1, 2013
JIMD Rep. 2013 Nov 5. [Epub ahead of print]
Newborn Screening for Glutaric Aciduria-II: The New England Experience.
Sahai I, Garganta CL, Bailey J, James P, Levy HL, Martin M, Neilan E, Phornphutkul C, Sweetser DA, Zytkovicz TH, Eaton RB.
New England Newborn Screening Program, University of Massachusetts Medical School, Jamaica Plain, MA, USA, firstname.lastname@example.org.
Newborn screening (NBS) using tandem mass spectrometry (MS/MS) permits detection of neonates with Glutaric Aciduria-Type II (GA-II). We report follow-up of positive GA-II screens by the New England Newborn Screening Program.Methods: 1.5 million infants were screened for GA-II (Feb 1999-Dec 2012). Specialist consult was suggested for infants with two or more acylcarnitine elevations suggestive of GA-II.Results: 82 neonates screened positive for GA-II, 21 weighing > 1.5 kg and 61 weighing ≤ 1.5 kg. Seven (one weighing < 1.5 kg), were confirmed with GA-II. Four of these had the severe form (died < 1 week). The other three have a milder form and were identified because of newborn screening. Two (ages > 5 years) have a G-Tube in place, had multiple hospitalizations and are slightly hypotonic. The third infant remains asymptomatic (9 months old). Two GA-II carriers were also identified. The remaining positive screens were classified as false positives (FP). Six infants (> 1.5 kg) classified as FP had limited diagnostic work-up. Characteristics and outcomes of all specimens and neonates with a positive screen were reviewed, and marker profiles of the cases and FP were compared to identify characteristic profiles.Conclusion: In addition to the severe form of GA-II, milder forms of GA-II and some GA-II carriers are identified by newborn screening. Some positive screens classified as FP may be affected with a milder form of the disorder. Characteristic GA-II profiles, quantified as GA-II indexes, may be utilized to predict probability of disorder and direct urgency of intervention for positive screens.
- [PubMed - as supplied by publisher]